Gemphire Therapeutics (NASDAQ:GEMP) had its price target increased by HC Wainwright from $22.00 to $28.00 in a report released on Friday, January 26th, MarketBeat reports. They currently have a buy rating on the stock.
Several other equities analysts have also issued reports on GEMP. Zacks Investment Research lowered Gemphire Therapeutics from a buy rating to a hold rating in a report on Wednesday, October 25th. Canaccord Genuity reissued a buy rating on shares of Gemphire Therapeutics in a report on Friday, October 13th. Roth Capital initiated coverage on Gemphire Therapeutics in a report on Thursday, October 19th. They set a buy rating and a $30.00 price objective for the company. Finally, Piper Jaffray Companies reissued an overweight rating and set a $22.00 price objective on shares of Gemphire Therapeutics in a report on Friday, October 27th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $23.17.
Gemphire Therapeutics (GEMP) opened at $6.26 on Friday. Gemphire Therapeutics has a 52 week low of $6.07 and a 52 week high of $21.59. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. The firm has a market capitalization of $66.56 and a P/E ratio of -2.16.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14). analysts anticipate that Gemphire Therapeutics will post -3.31 earnings per share for the current year.
In other news, insider Steven R. Ph.D. Gullans purchased 71,429 shares of the stock in a transaction on Thursday, February 8th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $500,003.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 34.00% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Comerica Bank bought a new stake in shares of Gemphire Therapeutics in the third quarter worth about $850,000. Northpointe Capital LLC grew its stake in shares of Gemphire Therapeutics by 91.8% in the third quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock worth $4,943,000 after purchasing an additional 249,077 shares during the last quarter. Bamco Inc. NY bought a new stake in shares of Gemphire Therapeutics in the third quarter worth about $2,709,000. Cambridge Investment Research Advisors Inc. grew its stake in shares of Gemphire Therapeutics by 4.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock worth $1,520,000 after purchasing an additional 6,900 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in shares of Gemphire Therapeutics in the second quarter worth about $139,000. 27.54% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/gemphire-therapeutics-gemp-price-target-raised-to-28-00.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.